The World's First TRILLION DOLLAR DRUG

Banyan Hill's STRATEGIC FORTUNES

The World's First Trillion-Dollar Drug

Get These 3 Biotech Stocks Before the FDA's Anticipated Announcement

By Ian King, Editor, *Strategic Fortunes*

THIS might be controversial but…

We might be witnessing weight loss drugs' biggest era since the 1990s.

As the Wall Street Journal puts it, we're seeing the birth of "one of the biggest drug categories of all time," and I couldn't agree more.

For the last two years, there's been an undeniable surge in popularity among Glucagon-like peptide-1s — or GLP-1 agonists — like Wegovy … Mounjaro … Zepbound …

And, perhaps, the biggest of them all (*and hardest to find*) — *Ozempic*.

These are Food and Drug Administration (FDA)-approved GLP-1 agonists used to treat diabetes, weight loss, heart disease, dementia, and a number of other diseases.

However, much of their popularity is due to their ability to aid in weight loss.

The Daily Mail writes, "Dieters [are] desperate for new 'miracle' weight drug" — and it seems everyone has been trying to get their hands on them in any way possible.

You see, per the CDC, 233 million Americans are reportedly overweight. However, less than 1% of the U.S. population has been using these drugs for weight loss — and that isn't because they don't want to.

They're seeing a massive surge in demand.

However, ABC News reports that "patients struggle to find Ozempic due to its popularity."

Now, when you look beyond just the U.S. and consider the 2.5 billion overweight people *worldwide*, these drugs could capture a huge market.

We're talking about 75,000% market growth potential here.

J.P. Morgan projects $72 billion in sales by 2030, while Goldman Sachs and Barclays expect $100 billion and $200 billion, respectively.

So, make no mistake about it — demand is soaring.

Sales went from practically nothing a few years ago to $19 billion in 2023.

The same could be said for Eli Lilly and Novo Nordisk, the biotech companies behind these drugs.

But these skyrocketing sales are just the tip of the iceberg for what's to come.

I believe the story here is bigger than this…

Much bigger.

I believe the FDA is on the cusp of making an announcement that could kick the sales of GLP-1 drugs into the stratosphere.

I see it creating the world's first trillion-dollar drug by 2030 and completely revolutionizing the $4.5 trillion healthcare industry.

And I'm not talking about Novo Nordisk and Eli Lilly.





After all this growth, these are the two biggest pharmaceutical companies in the world now.

So, at this point, it's too late for you to enter those stocks and make any *real* money.

But if you missed the money train on those opportunities, now's your chance to take advantage of the next.

Remember, these drugs do a lot more than just reverse obesity.

New clinical trial results show they can stop and, in some cases, reverse anything from heart disease to Alzheimer's to arthritis, depression, and more.

So, I believe that, at some point, before the year is up, the FDA will begin approving GLP-1 drugs to treat additional diseases as well.

This is where the real opportunity lies — because that could allow billions of new wealth to flow into these drugs. That's why I recommend buying into three smaller biotech stocks with massive upside … I'm talking about investments powerful enough to make early investors a small fortune.

Because over the next 12 to 24 months, I believe any one of today's recommendations could greatly outperform the returns we've seen so far.

Recommendation No. 1: Dexcom

This brings me to our first pick — **Dexcom (Nasdaq: DXCM)** — a fast-growing biotech following the Apple playbook.

Apple spent decades building computer hardware before the internet took off, ensuring they were well-positioned to capitalize when millions of people started going online.

Dexcom also builds hardware — only theirs helps people with diabetes use GLP-1 drugs safely.

You see, the traditional method of monitoring and managing diabetes comes with a couple of downsides.

Not only does it involve pricking your fingers and using test strips and glucose meters to measure blood sugar levels, but you can only get a reading when you check.

However, the modern method, a continuous glucose monitoring (CGM) device, has much better upside.

CGM devices place a small sensor just under the skin, usually on the belly or arm, for a continuous reading.

From there, the sensor transmits glucose levels using a small external receiver.

So, the market's shift toward these devices — like the ones Dexcom makes — has been a much more pleasant experience.

It has also led to DCOM experiencing explosive growth. In the first quarter (Q1) of 2024, revenue was up 24% year-over-year.

Although the majority of Dexcom's revenue has been generated in the U.S., the company expanded its operations to include certain countries in Africa, Asia, Australia, Canada, Europe, Latin America, the Middle East and New Zealand.

Dexcom is partnering with major players in the biotech space to develop combined glucose monitoring and insulin delivery systems. Among these partners are Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes and The Ypsomed Group.

Dexcom is laser-focused on remaining a leading provider of CGM systems and related products to give type 1 and type 2 diabetes patients a more effective and convenient way to manage their disease.



Dexcom is also developing and commercializing products that integrate CGM technologies into its respective partners' insulin delivery systems or data platforms.

Even better, it's managing to do this while continuing to develop partnerships with other insulin delivery companies, including automated insulin delivery systems.

Per Mordor Intelligence, the CGM device market is expected to witness a compound annual growth rate (CAGR) of nearly 12.9% between 2021 and 2029, with strong growth in the Asia Pacific region.

The market is expected to reach $21.34 billion by 2029.

CGM Market Represents a Huge Potential

With more than 130 million people with diabetes or prediabetes in the U.S., the diabetes market represents a huge market potential.

Currently, more than 400 million people have diabetes worldwide, and I expect that number to grow in the coming years.

The rising prevalence of diabetes drives the demand for CGM devices.

The increasing incidence of prediabetes also represents an opportunity for growth. The global CGM device market is estimated at a CAGR of nearly 10% from more than $6 billion currently and will reach $14 billion by 2032.

As one of the leaders in the CGM-device market, Dexcom is expected to show strong growth over the next decade, based on market growth and rising penetration of CGM devices.

Although GLP-1 drugs Ozempic and Mounjaro, which were initially developed for diabetes patients and later adapted to fight obesity, were initially considered to be headwinds for companies like Dexcom, the data shows the opposite.



Dexcom's data from healthcare providers matches the data collected by its competitor, Abbott Laboratories, regarding GLP-1 drugs and CGMs.

The data showed that since 2018, clinicians have been pairing CGMs with GLP-1 drugs because a combined approach is believed to be a better therapy.

This is because a CGM can act as a monitoring and accountability device for the effects of GLP-1 drugs on patient behaviors.

In other words, GLP-1s could actually boost the adoption of CGMs by more people.

Dexcom also recently released Stelo, a new CGM that is available over the counter without a prescription.

This will further open up the market to users who want to pair a CGM with their GLP-1 drugs to stay on track with their weight loss journey.

I believe Dexcom's large and growing diabetes market, strong product portfolio, partnerships, and focus on international markets show it has major profit potential.

Action to Take: Buy Dexcom (Nasdaq: DXCM).

Recommendation No. 2: HIMS

Our next recommendation, **Hims & Hers Health (NYSE: HIMS)**, is a tiny biotech company that follows direct-to-consumer sales — the business model that took Amazon to the top.

In HIMS' case, it is considered a direct-to-consumer pharmaceutical start-up.

This online health and wellness telehealth platform connects patients to licensed health care professionals in all 50 U.S. states and is on a mission to help people feel great through the power of better health.

HIMS specializes in normalizing most health and wellness challenges while innovating solutions to these problems.

HIMS' telehealth platform allows consumers to access medical care for everything from skincare to hair loss to mental health, sexual wellness — even primary care.

HIMS does it *all*.

No wonder its revenue is up almost 200% in the last two years…

HIMS' core offerings are in skin and hair care, sexual health products, mental health products, supplements and more.

However, its newest offering is where the biggest upside potential lies.

Hims & Hers Health's share price rose more than 25% after announcing the availability of compounded GLP-1 agonist weight loss drugs at an 85% discount to Wegovy and Zepbound!

Remember, these drugs are in high demand. And as a result, they're experiencing shortages.

HIMS also aims to capitalize on the shortages of Wegovy and Zepbound, which are expected to dominate a potential $100 billion industry.

In a press release, Hims & Hers recently stated:

"Providing access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic® and Wegovy® without navigating the shortages and costs that are currently limiting access to the branded medications."

Hims & Hers' partnership with a manufacturer of generic and compounded medications allows it to offer these drugs without supply shortages, potentially generating significant revenue.

Andrew Dudum, CEO and co-founder of Hims & Hers, stated:

"We've leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today. We're passing that access and value along to our customers, who deserve the highest standard of clinical safety and efficacy to meet their goals, and we're doing it in a safe, affordable way that others can't deliver."

And with the Nasdaq calling direct-to-consumer drug sales “the new era of pharma,” I expect HIM’s stock to skyrocket as the popularity of GLP-1 drugs continues to surge.

Most of Hims & Hers’ revenues derive from subscription fees. This allows users to access certain products and services online, including prescription products, which can be obtained through online consultations with partnered physicians.

In short, Hims & Hers is a very good fit for patients seeking weight loss solutions and well positioned to take advantage of the current Wegovy / Zepbound shortage.

Additionally, HIMS’ subscriber base has continued to expand.



As of Q1 of 2024, the company reported 1.7 million subscribers — up from 1.2 million in the year prior.



In the first quarter of 2024, HIMS saw a significant increase in revenue, earning $278 million, versus $191 million in Q1 of 2023.

Looking ahead, it is forecasting between $292 million to $297 million in the second quarter (Q2) of 2024 and full-year 2024 revenues of $1.2 billion to $1.23 billion, with adjusted EBITDA of $120 million to $135 million.

HIMS' current revenue is expected to grow exponentially in the coming years, provided supply can meet demand.

With that said, the potential opportunity at play for HIMS could be significant.

Action to Take: Buy Hims & Hers Health (NYSE: HIMS).

Recommendation No. 3: GPCR

Headquartered in San Francisco, our third breakout stock is **Structure Therapeutics (Nasdaq: GPCR)** — a clinical-stage biotech company with *massive* potential.

Structure Therapeutics develops small molecule therapeutics to treat various diseases impacting the metabolic, cardiovascular and pulmonary systems.

Within the next year, I believe it could get FDA approval for a new GLP-1 drug, which could cause GPCR to surge 10X … 30X … or even 50X in a matter of months, weeks, or even days.

And the latest news speaks to GPCR's potential to rocket higher over time.

The stock soared 60% in early June after it reported promising results for its mid-stage weight loss pill studies.

In the study, patients experienced an average of 6.2% weight loss after just 12 weeks of treatment using Structure's "small molecule" pill, with one-third losing more than 10% of their weight.

Following this report, Raymond Stevens, Chief Executive of Structure Therapeutics, stated:

"Our large-scale manufacturing process is expected to be more than capable of meeting the anticipated global demand of a product."

While this is comparable to one of its main competitor's brands', Eli Lilly's oforglipron pill, the two have major differences.

For example, Structure is developing a treatment that can be taken orally instead of by injection, like Wegovy and Zepbound.

Much like Eli Lilly's Ozempic, Structure's lead candidate, GSBR-1290, works as a semaglutide to manage food cravings.

However, because Structure uses small molecule pills, they require fewer manufacturing steps than peptides.

For small molecules, we're talking between 8 to 10 steps, whereas peptides could take as much as 106 steps to manufacture.

More importantly, however, Structure is focused on solving the main problem with these GLP-1 drugs…

Cost.

The journal Medicine in Drug Discovery reports that drugs like peptides cost — on average — 22 times more to make than typical small-molecule drugs.



As it currently stands, a one-month dose of these drugs could cost around $1,000 without a prescription.

Because, again, peptides are more complex, so they tend to cost a lot more…

As in, over 10 times more!

However, Structure Therapeutics has stepped in to fulfill a need with its small molecule version of these weight loss drugs.

Using proprietary manufacturing processes could potentially cut costs as low as $200 a month — or *one-fifth* of the current costs of these drugs.

Action to Take: Buy Structure Therapeutics (Nasdaq: GPCR).

With each of these biotech breakout stocks currently in the FDA approval process, I recommend buying now.

Because if you can get in on a tiny biotech company before it gets FDA approval for a new drug, the potential opportunity for massive gains can be extraordinary.

As the frenzy for GLP-1 drugs continues to pick up steam, I expect these three will have the potential to turn a tiny stake into a small fortune.

That's all for now. In the meantime, if you have questions about any of the recommendations in this report, feel free to reach out at StrategicFortunes@BanyanHill.com.

Regards,

Ian King
Editor, *Strategic Fortunes*

Banyan Hill
P.O. Box 8378
Delray Beach, FL 33482 USA
USA Toll Free Tel.: (866) 584-4096

Email: http://banyanhill.com/contact-us

Website: www.banyanhill.com

LEGAL NOTICE: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Banyan Hill Publishing permits editors of a publication to recommend a security to subscribers that they own themselves. However, in no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Any exit after a buy recommendation is made and prior to issuing a sell notification is forbidden. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication.